The exceptionally broad-based potential of active and passive vaccination targeting the conserved microbial surface polysaccharide PNAG.

摘要: A challenging component of vaccine development is the large serologic diversity protective antigens. Remarkably, there a conserved surface/capsular polysaccharide, one most effective targets, expressed by number bacterial, fungal and eukaryotic pathogens: poly-N-acetyl glucosamine (PNAG). Natural antibodies to PNAG are poorly at mediating in vitro microbial killing or vivo protection. Removing acetate substituents produce deacetylated glycoform, using synthetic oligosaccharides poly-β-1-6-linked conjugated carrier proteins, results vaccines that elicit high levels broad-based immunity. fully human monoclonal antibody highly active laboratory preclinical studies has been successfully tested phase-I setting. Both oligosaccharide conjugate MAb will be further humans starting 2016; but, even if against only fraction PNAG-producing pathogens, major advance vaccine-preventable diseases occur.